D M Vigushin

Summary

Affiliation: Imperial College
Country: UK

Publications

  1. ncbi Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells
    John P Alao
    Department of Cancer Medicine, Imperial College, Hammersmith Hospital, London, W12 0NN, UK
    Mol Cancer 5:8. 2006
  2. ncbi The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines
    John P Alao
    Department of Cancer Medicine, Imperial College, Hammersmith Hospital, London, W12 0NN, UK
    Mol Cancer 5:7. 2006
  3. ncbi The nuclear oxysterol receptor LXRalpha is expressed in the normal human breast and in breast cancer
    D M Vigushin
    Department of Cancer Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN
    Med Oncol 21:123-31. 2004
  4. ncbi Pyrazino[1,2-a]indole-1,4-diones, simple analogues of gliotoxin, as selective inhibitors of geranylgeranyltransferase I
    David M Vigushin
    Department of Cancer Medicine, 6th Floor MRC Cyclotron Building, Imperial College of Science, Technology and Medicine, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK
    Bioorg Med Chem Lett 13:3661-3. 2003
  5. ncbi Gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase I with antitumor activity against breast cancer in vivo
    D M Vigushin
    Department of Cancer Medicine, 6th Floor MRC Cyclotron Building, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK
    Med Oncol 21:21-30. 2004
  6. ncbi Targeted histone deacetylase inhibition for cancer therapy
    D M Vigushin
    Department of Cancer Medicine, Imperial College, Hammersmith Campus, London W12 0NN, UK
    Curr Cancer Drug Targets 4:205-18. 2004
  7. ncbi Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo
    D M Vigushin
    Department of Cancer Medicine, Cancer Research Campaign Laboratories, Imperial College of Science, Technology, and Medicine, Hammersmith Hospital, London, United Kingdom
    Clin Cancer Res 7:971-6. 2001
  8. ncbi Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice
    L Sanderson
    Department of Cancer Medicine, 6th Floor MRC Cyclotron Building, Imperial College London (Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, United Kingdom
    Drug Metab Dispos 32:1132-8. 2004
  9. ncbi Managing malignant disease in patients with porphyria
    C Palmieri
    Department of Cancer Medicine, Faculty of Medicine, Imperial College London, UK
    QJM 97:115-26. 2004
  10. ncbi Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase
    Charles M Marson
    Department of Chemistry, University College London, Christopher Ingold Laboratories, 20 Gordon Street, London WC1H OAJ, UK
    Bioorg Med Chem Lett 17:136-41. 2007

Collaborators

Detail Information

Publications21

  1. ncbi Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells
    John P Alao
    Department of Cancer Medicine, Imperial College, Hammersmith Hospital, London, W12 0NN, UK
    Mol Cancer 5:8. 2006
    ..TSA treatment also resulted in accumulation of polyubiquitylated GFP-cyclin D1 species and reduced levels of the recombinant protein within the nucleus...
  2. ncbi The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines
    John P Alao
    Department of Cancer Medicine, Imperial College, Hammersmith Hospital, London, W12 0NN, UK
    Mol Cancer 5:7. 2006
    ..Additional studies were initiated in order to further investigate the effect of TSA on cyclin D1 regulation using sub-cellular fractionation techniques...
  3. ncbi The nuclear oxysterol receptor LXRalpha is expressed in the normal human breast and in breast cancer
    D M Vigushin
    Department of Cancer Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN
    Med Oncol 21:123-31. 2004
    ..Inhibition of breast cancer cell proliferation suggests that pharmacological LXRalpha agonists may have potential preventive and/or therapeutic antitumor activity in breast cancer...
  4. ncbi Pyrazino[1,2-a]indole-1,4-diones, simple analogues of gliotoxin, as selective inhibitors of geranylgeranyltransferase I
    David M Vigushin
    Department of Cancer Medicine, 6th Floor MRC Cyclotron Building, Imperial College of Science, Technology and Medicine, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK
    Bioorg Med Chem Lett 13:3661-3. 2003
    ....
  5. ncbi Gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase I with antitumor activity against breast cancer in vivo
    D M Vigushin
    Department of Cancer Medicine, 6th Floor MRC Cyclotron Building, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK
    Med Oncol 21:21-30. 2004
    ..The present studies confirm that gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase I with pronounced antitumor activity and favorable toxicity profile against breast cancer in vitro and in vivo...
  6. ncbi Targeted histone deacetylase inhibition for cancer therapy
    D M Vigushin
    Department of Cancer Medicine, Imperial College, Hammersmith Campus, London W12 0NN, UK
    Curr Cancer Drug Targets 4:205-18. 2004
    ..This report reviews the biology and clinical development of histone deacetylase inhibitors for cancer therapy...
  7. ncbi Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo
    D M Vigushin
    Department of Cancer Medicine, Cancer Research Campaign Laboratories, Imperial College of Science, Technology, and Medicine, Hammersmith Hospital, London, United Kingdom
    Clin Cancer Res 7:971-6. 2001
    ....
  8. ncbi Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice
    L Sanderson
    Department of Cancer Medicine, 6th Floor MRC Cyclotron Building, Imperial College London (Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, United Kingdom
    Drug Metab Dispos 32:1132-8. 2004
    ..We conclude that trichostatin A is rapidly and extensively metabolized in vivo following intraperitoneal administration to mice, and N-demethylation does not compromise histone deacetylase-inhibitory activity...
  9. ncbi Managing malignant disease in patients with porphyria
    C Palmieri
    Department of Cancer Medicine, Faculty of Medicine, Imperial College London, UK
    QJM 97:115-26. 2004
    ..We briefly review the biochemical basis, clinical features and current management of porphyria in cancer patients...
  10. ncbi Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase
    Charles M Marson
    Department of Chemistry, University College London, Christopher Ingold Laboratories, 20 Gordon Street, London WC1H OAJ, UK
    Bioorg Med Chem Lett 17:136-41. 2007
    ..Variation of the substituents on the benzene ring as well as fusion of a second ring have marked effects on potency, in vitro IC(50) values down to 1 nM being obtained...
  11. ncbi In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography
    Julius Leyton
    Molecular Therapy and Cancer Cell Biology, Imperial College London, Faculty of Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, United Kingdom
    Cancer Res 66:7621-9. 2006
    ..Drug-induced changes in tumor [18F]FLT uptake were due, at least in part, to reductions in TK1 transcription and translation...
  12. ncbi Histone deacetylase inhibitors in cancer treatment
    David M Vigushin
    Department of Cancer Medicine, Imperial College of Science, Technology and Medicine, Hammersmith Hospital Campus, London W12 0NN, UK
    Anticancer Drugs 13:1-13. 2002
    ..The focus of this review is the development and clinical application of HDAC inhibitors for the treatment of cancer...
  13. ncbi Targeted histone deacetylase inhibition for cancer prevention and therapy
    Carlo Palmieri
    Department of Cancer Medicine, 7th Floor MRC Cyclotron Building, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK
    Prog Drug Res 63:147-81. 2005
  14. ncbi Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines
    John Patrick Alao
    Department of Cancer Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, United Kingdom
    Clin Cancer Res 10:8094-104. 2004
    ..Taken together, our data show that TSA effectively induces cyclin D1 down-regulation through both ERalpha-dependent and ERalpha-independent mechanisms, providing an important new strategy for combating resistance to antiestrogens...
  15. ncbi ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor alpha from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line
    Rana Varshochi
    Cancer Research UK Laboratories and Section of Cancer Cell Biology, Department of Cancer Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 ONN, United Kingdom
    J Biol Chem 280:3185-96. 2005
    ....
  16. ncbi Increased gestational age at evacuation of a complete hydatidiform mole: does it correlate with increased risk of requiring chemotherapy?
    Michael J Seckl
    Charing Cross Gestational Trophoblastic Disease Unit, Imperial College, London, UK
    J Reprod Med 49:527-30. 2004
    ..To assess whether a complete hydatidiform mole (CHM) carries an increased risk of later requiring chemotherapy in pregnancies continued to term...
  17. ncbi FR-901228 Fujisawa/National Cancer Institute
    David M Vigushin
    Department of Cancer Medicine, MRC Cyclotron Building, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK
    Curr Opin Investig Drugs 3:1396-402. 2002
    ..The depsipeptide FR-901228 is a histone deacetylas inhibitor under development by Fujisawa and the National Cancer Institute as a potential treatment for neoplasm. By May 2002, phase II trials had commenced in the US [452248], [461017]...
  18. ncbi Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides
    Charles M Marson
    Department of Chemistry, University College London, Christopher Ingold Laboratories, 20 Gordon Street, London WC1H OAJ, UK
    Bioorg Med Chem Lett 14:2477-81. 2004
    ..Variation of substituents on the aromatic ring has a marked effect on potency, in vitro IC(50) values down to 50 nM being obtained...
  19. ncbi Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods
    Laura M Kenny
    Molecular Therapy and PET Oncology Research Group, Hammersmith Hospital, London, UK
    Cancer Res 65:10104-12. 2005
    ..We conclude that [18F]FLT-positron emission tomography is a promising clinical tool for imaging cellular proliferation in breast cancer, and is most predictive when analyzed by graphical and spectral methods...
  20. ncbi Cyclic acid anhydrides as a new class of potent, selective and non-peptidic inhibitors of geranylgeranyl transferase
    Charles M Marson
    Department of Chemistry, University College London, Christopher Ingold Laboratories, 20 Gordon Street, London WC1H OAJ, UK
    Bioorg Med Chem Lett 12:255-9. 2002
    ..Cyclic acid anhydrides possessing a lipid chain have been shown to be a new class of non-peptidic inhibitors of geranylgeranyl protein-transferase type I (GGPTase-I)...
  21. ncbi Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography
    Laura Kenny
    Imperial College London, and Hammersmith Hospital NHS Trust, London, UK
    Eur J Nucl Med Mol Imaging 34:1339-47. 2007
    ..The aims of this pilot study were to define objective criteria for [18F]FLT response and to examine whether [18F]FLT-PET can be used to quantify early response of breast cancer to chemotherapy...